Recros Medica is a technology company.
Recros Medica has raised $9.0M across 1 funding round.
Recros Medica has raised $9.0M in total across 1 funding round.
Recros Medica has raised $9.0M in total across 1 funding round.
Recros Medica's investors include Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, Longwood Fund, Polaris Partners.
Recros Medica is a medical device company specializing in developing innovative technologies to treat skin laxity and focal aesthetic contour deformities. Their core product platform, called Rotational Fractional Resection, targets multiple clinical applications in the medical aesthetics field, aiming to improve patients' appearance by addressing common skin and contour issues. The company serves medical professionals and aesthetic practitioners who require advanced, effective solutions for non-invasive or minimally invasive cosmetic treatments. Recros Medica is positioned in the growing aesthetic medical device market, leveraging technology to meet increasing demand for skin rejuvenation and contour correction[1][3][4].
Recros Medica was founded as a privately held company focused on research, development, and manufacturing of aesthetic medical products. While specific founding year and founders' details are not publicly detailed, the company has evolved around its proprietary technology platform, Rotational Fractional Resection, which represents a novel approach in the aesthetic device space. Early traction likely came from clinical validation and adoption by aesthetic practitioners seeking improved treatment modalities for skin laxity and contour deformities[3][4].
Recros Medica operates within the expanding medical aesthetics market, which is driven by increasing consumer demand for minimally invasive cosmetic procedures and technological advancements in skin treatment. The timing is favorable due to rising awareness of aesthetic health, aging populations, and technological progress in medical devices. By introducing a novel technology platform, Recros Medica contributes to advancing treatment options, potentially influencing standards of care and encouraging further innovation in the aesthetic device ecosystem[1][3].
Looking ahead, Recros Medica is poised to capitalize on growing market trends favoring non-invasive aesthetic treatments. Continued clinical validation, regulatory approvals, and adoption by practitioners will be critical to their growth momentum. Emerging trends such as personalized aesthetic treatments and integration of digital technologies could shape their product evolution. As the company expands its clinical applications and market reach, it may become a significant player influencing the future landscape of medical aesthetics, tying back to its mission of enhancing appearance through innovative technology[1][3][4].
Recros Medica has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Venture Round in January 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2018 | $9.0M Venture Round | Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, Longwood Fund, Polaris Partners |